H. Woerle

发表

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

H. Woerle, A. Barnett, G. Schernthaner, 2012, Diabetes, obesity & metabolism.

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

H. Woerle, T. Haak, T. Meinicke, 2012, Diabetes, obesity & metabolism.

The dipeptidyl peptidase‐4 inhibitor linagliptin lowers postprandial glucose and improves measures of β‐cell function in type 2 diabetes

T. Heise, S. Patel, H. Woerle, 2014, Diabetes, obesity & metabolism.

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

R. Gomis, H. Woerle, H. Woerle, 2011, Diabetes, obesity & metabolism.

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin *

T. Heise, H. Woerle, H. Woerle, 2011, Diabetes, obesity & metabolism.

Reduction in cardiovascular death with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: Results from EMPA-REG OUTCOME

B. Zinman, S. Inzucchi, C. Wanner, 2018, Diabetologie und Stoffwechsel.

Long‐term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes

R. Kawamori, H. Watada, E. Araki, 2013, Diabetes, obesity & metabolism.

Safety and tolerability of empagliflozin in patients with type 2 diabetes

U. Broedl, H. Woerle, A. Salsali, 2016 .

Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c

D. Fitchett, S. Inzucchi, J. George, 2018 .

P4903Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c

D. Fitchett, J. McKnight, S. Inzucchi, 2017 .

Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β‐hydroxysteroid dehydrogenase‐1 (HSD1) inhibitor in humans: liver and adipose tissue 11β‐HSD1 inhibition after acute and multiple administrations over 2 weeks

T. Heise, H. Woerle, H. Woerle, 2016, Diabetes, obesity & metabolism.

Response Letter to D. Singh‐Franco et al.

D. Owens, M. Taskinen, R. Gomis, 2012, Diabetes, obesity & metabolism.

Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

M. Taskinen, J. Rosenstock, H. Woerle, 2011, Diabetes, obesity & metabolism.

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment

D. Owens, M. Taskinen, P. Groop, 2014, Diabetes, obesity & metabolism.

Lack of drug–drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers

H. Woerle, P. Rose, M. Mattheus, 2013, Diabetes, obesity & metabolism.

Empagliflozin as add‐on to metformin in people with Type 2 diabetes

U. Broedl, H. Woerle, H. Woerle, 2015, Diabetic medicine : a journal of the British Diabetic Association.

Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with Type 2 Diabetes (T2DM): Pooled data from four pivotal phase III trials

U. Broedl, J. Gerich, H. Woerle, 2014 .

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study

H. Woerle, H. Woerle, M. von Eynatten, 2013, International journal of clinical practice.

Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24‐week randomized study 1

D. Owens, H. Woerle, H. Woerle, 2011, Diabetic medicine : a journal of the British Diabetic Association.

Effect of linagliptin monotherapy on glycaemic control and markers of β‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

S. Del Prato, H. Woerle, A. Barnett, 2011, Diabetes, obesity & metabolism.

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18‐week randomized, double‐blind, placebo‐controlled phase III trial with a 34‐week active‐controlled extension

A. Barnett, S. Patel, H. Woerle, 2012, Diabetes, obesity & metabolism.

Safety and efficacy of the dipeptidyl peptidase‐4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years

H. Woerle, A. Barnett, G. Schernthaner, 2014, Diabetes, obesity & metabolism.

Empagliflozin reduces mortality in analyses adjusted for control of blood pressure, low density lipoprotein cholesterol and HbA1c over time

B. Zinman, D. Fitchett, H. Woerle, 2017, Diabetologie und Stoffwechsel.

Empagliflozin (EMPA) increases genital infections but not Urinary Tract Infections (UTIs) in pooled data from four pivotal phase III trials

U. Broedl, J. Gerich, H. Woerle, 2014 .

Effect of Empagliflozin On Cardiovascular Death in Subgroups Byage: Results From Empa-Reg Outcome

B. Zinman, D. Fitchett, S. Inzucchi, 2016 .

Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Glimepiride Following Co-administration in Healthy Volunteers: A Randomised, Open-label, Crossover Study

H. Woerle, H. Woerle, M. Mattheus, 2012 .

Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial

J. Rosenstock, H. Woerle, B. Gallwitz, 2015, Diabetes, obesity & metabolism.

Linagliptin provides effective, well‐tolerated add‐on therapy to pre‐existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes

H. Watada, S. Patel, H. Woerle, 2013, Diabetes, obesity & metabolism.

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials

U. Broedl, H. Woerle, H. Woerle, 2016, Diabetes, obesity & metabolism.